|
|
|
|
The global biologics pipeline is growing and diversifying, leading to increased demand for manufacturing capacity. As a result, the bioprocessing industry is investing in new technologies to enable efficiency and productivity. One such technology is the XCell® Alternating Tangential Flow (ATF) System, which has been adopted for perfusion-based upstream intensification.
|
|
|
|
|
As viral vaccine demand grows, manufacturers face facility constraints that limit batch scaling. Perfusion technology offers a smart solution — enabling higher cell densities in existing equipment while maintaining optimal nutrient delivery and waste removal. The result: greater productivity, process efficiency, and product quality without expanding your facility footprint.
|
|
|
|
|
The rapid growth of innovative cell therapies — especially CAR-T — has driven soaring demand for lentiviral vectors, essential for cell engineering. Yet, traditional production methods can't keep up, creating a bottleneck in delivering these life-changing therapies. Scalable, high-yield solutions are needed to meet clinical demand and unlock the full potential of cell therapy.
|
|
|
|
|
To meet the soaring demand for viral vectors in gene therapy, manufacturing must evolve. Using an integrated perfusion strategy with the KrosFlo® TFDF® system, we significantly intensified both cell growth and vector production. By implementing perfusion before transfection, we achieved a 3x increase in cell density — reaching ~9M cells/mL vs. ~3M in batch — driving greater upstream efficiency and output.
|
|
|
|
|
Biotherapeutic manufacturers are moving beyond batch and fed-batch methods to meet the rising demand for advanced therapies. In this Repligen-hosted webinar, industry leaders explore how continuous manufacturing — pioneered in mAb production — is being applied to ATMPs like gene and cell therapies, mRNA, and vaccines to boost productivity, lower costs, and ensure product quality at scale.
|
|
|
|
|
|
XCell® ATF System: Breaking Productivity Barriers In Upstream Bioprocessing
|
The XCell® ATF System is an innovative solution designed to address the growing need for efficient and cost-effective biotherapeutic manufacturing. This advanced system utilizes Alternating Tangential Flow (ATF) technology to enable continuous bioprocessing through perfusion cell culture. This process allows for longer run times and higher viable cell densities, resulting in increased productivity and reduced costs.
|
|
• Request Information
|
|
|
|
|
|
|
|
